Source: European Medicines Agency (EU) Revision Year: 2020 Publisher: gmp-orphan SA, Pépinière Paris Santé Cochin, 27-29 rue du Faubourg Saint-Jacques, 75014, Paris, France
Cuprior 150 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet (tablet). Yellow, 16 mm x 8 mm oblong film-coated tablet with a score line on each side. The tablet can be divided into equal doses. |
Each film-coated tablet contains trientine tetrahydrochloride equivalent to 150 mg trientine.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Trientine |
Trientine is a copper-chelating agent whose principal mechanism of action is to eliminate absorbed copper from the body by forming a stable complex that is then eliminated through urinary excretion. Trientine may also chelate copper in the intestinal tract and so inhibit copper absorption. |
| List of Excipients |
|---|
|
Tablet core: Mannitol Tablet film-coating: Polyvinyl alcohol |
OPA/Alu/PVC-Alu blisters, each blister contains 8 film-coated tablets.
Pack size: 72 or 96 film-coated tablets.
Not all pack sizes may be marketed.
gmp-orphan SA, Pépinière Paris Santé Cochin, 27-29 rue du Faubourg Saint-Jacques, 75014, Paris, France
EU/1/17/1199/001
Date of first authorisation: 5 September 2017
| Drug | Countries | |
|---|---|---|
| CUPRIOR | Austria, Estonia, Finland, France, Croatia, Ireland, Lithuania, Netherlands, New Zealand, Poland, Romania, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
